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Use of digital resource centers for atopic dermatitis patients,
caregivers, and health care professionals to improve shared
decision-making and proactive management
Linda Stein Gold, MD, Henry Ford Health System; Adam J. Friedman,
MD, FAAD, GW School of Medicine and Health Sciences; Kanwaljit Brar, MD,
FAAAAI, FACAAI, NYU School of Medicine
Overview: To close gaps in atopic dermatitis (AD) care, we developed and analyzed
aligned resource centers for patients/caregivers and health care professionals
(HCPs).
Methods: The patient resource center was designed to support patients/caregivers
in being more proactive in their AD care. The HCP-targeted resource center aimed to
increase their awareness of AD patient perspectives and improve communication.
Surveys were completed by users of both resource centers.
Results: Of the 1014 HCPs, 22% were physicians (30% specialists), 19% were nurse
practitioners/physician assistants, 47% were nurses, and 12% were pharmacists.
Approximately one-half of 801 patients (98% adults) reported that they only treat
their AD when experiencing a flare, and only 30% were very satisfied with their care.
Only 56% indicated that they make all decisions with their HCP, and only 22% of
HCPs reported that they always involve their AD patients/caregivers in shared
decision-making. Only 21% of patients always share preferences, goals, or concerns
about AD with their HCP, and only 6% of HCPs rated their ability to ask about and
understand the impact of AD on patients’ quality of life as ‘‘very good.’’ Actions that
patients planned to take included proactive skin care, asking their HCP about
additional treatment options, and telling their HCP about the impact of AD on their
quality of life. Nearly 60% of 764 HCPs planned to educate AD patients/caregivers
about treatment options and expectations.
Conclusions: These results highlight communication gaps between AD patients/caregivers and HCPs. Insights from these data can be used to improve shared
decision-making.
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Usefulness of noninvasive management with the gutter method
for epidermal growth factor receptor inhibitor-induced paronychia, pyogenic granuloma-like lesion, and ingrown nail
Ai Agematsu, MD, Department of Dermatology, Teikyo University
School of Medicine; Masahiro Kamata, MD, PhD, Department of Dermatology,
Teikyo University School of Medicine; Kaoru Namiki, MD, PhD, Department of
Dermatology, Teikyo University School of Medicine
Background: Nail complications such as paronychia, pyogenic granuloma-like
lesions, and ingrown nail are common adverse events of epidermal growth factor
receptor (EGFR) inhibitors. They frequently cause severe pain and are refractory.
The gutter method is a nonsurgical treatment for ingrown nail in which a plastic
tube is inserted between the nail plate and the nail fold. Reports on its effectiveness
for EGFR inhibitor-induced nail complications are quite limited.
Objective: We investigated characteristics of EGFR-inhibitor-induced nail complications and usefulness of the gutter method.
Methods: Patients with EGFR inhibitor-induced nail complications treated with the
gutter method were included in this study. ‘‘Treatment success’’ was defined as
conditions in which no ulcer, pyogenic granuloma-like lesion, nor pain is observed
within one month after the first gutter method treatment.
Results: Data on 11 patients were analyzed. The mean time at onset of nail
complications after initiating an EGFR inhibitor was 10.0 6 6.3 weeks. The nail
complications occurred the most frequently at the great toe. Nine in 11 patients
achieved ‘‘treatment success’’. The pain VAS scores significantly decreased from 71.4
6 12.7 to 15.1 6 16.1 in one week (P ¼ .0156). Limitations: The small number of
cases.
Conclusion: The noninvasive management with gutter method treatment is useful
for EGFR-induced nail complications.
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Use of topical tranexamic acid in patients with melasma: A
narrative review
Taylor Thieman, BS, University of Nebraska Medical Center, College of
Medicine; Ritu Swali, MD, University of Nebraska Medical Center,
Department of Dermatology; Jennifer Adams, MD, University of Nebraska
Medical Center, Department of Dermatology
Background: Oral tranexamic acid (TXA) is an effective treatment for melasma likely
via its effects on the plasminogen pathway. However, there are several potential side
effects including thromboembolism. Topical TXA may be useful for melasma, but
the efficacy is largely unknown.
Objectives: To determine the efficacy of topical TXA for melasma by reviewing
studies comparing topical TXA to oral TXA and other topicals. Additionally, to
determine if methods that may improve penetrance increase the potential benefit
and to summarize any reported side effects.
Methods: A review of the literature was performed for studies using topical TXA for
melasma.
Results: Only one study compared oral to topical TXA, with superior results from
oral TXA. But several studies compared withpical TXA to topical hydroquinone
(HQ) and all found similar decreases in Melasma Area Severity Index scores.
However, there were more side effects (erythema and irritation) and lower patient
satisfaction with HQ. Two studies found that topical TXA with micro-needling may
significantly improve results compared with topical TXA alone and one study found
that combined use with a fractional CO2 laser also improved results. Most studies
used 5% TXA solution twice daily.
Discussion: Overall, topical TXA may be as effective as topical HQ, but TXA may be
better tolerated. Concomitant micro-needling or laser treatment likely increases the
benefit but there are limited studies. There is also limited evidence comparing oral to
topical TXA but given the known risks with oral TXA, topical TXA may be a
reasonable and safe treatment option for melasma.
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Using shared decision-making communication strategies to
improve outcomes for patients with atopic dermatitis: Results
of a national scope continuing medical education initiative
Stephen T. Bender, FACTORx, LLC; Derek Dietze, MA, FACEHP, CHCP,
Metrics for Learning; Andrea Funk, Global Education Group
An online national-scope 1-credit continuing medical education (CME) activity
targeted at primary care clinicians, pediatricians, dermatologists, and allergists
focused on educating as many clinicians as possible on what shared decision-making
(SDM) is and how it can improve outcomes in patients with atopic dermatitis (AD). It
also encouraged providers to share National Eczema Association’s patient platform,
EczemaWise, with as many patients as possible. The activity, available through three
of the largest CME distribution channels in the United States, included video
vignettes with examples of effective communication and SDM between real
clinicians and patients with AD. The initiative educated 17,940 learners, and 400
patients enrolled in EczemaWise. Based on 5 pre/post multiple choice questions,
knowledge test scores increased statistically significantly and similarly across each of
the 3 distribution channels, ranging from 60%-62% correct pre to 89%-93% correct
post (P \.001, paired t-test, large effect size for each—Cohen’s d $ 1.15). 12,130
learners had National Provider Identifier numbers, of which 5698 were matched
against a national medical claims database (de-identified, HIPAA-compliant) to
objectively determine the number of patients with AD the learners treat annually.
Verified in the claims data, these learners managed at least 31,830 patients already
diagnosed with AD, in the last year. This indicates the scope of potential positive
impact on patients with AD based on the significant and large increases in
knowledge among the learners. The cost of development, implementation, and
evaluation of the initiative per confirmed patient with AD ranged from $4.47 to
$11.15, depending on the distribution channel.
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